Sanofi Pasteur Makes Progress with Dengue Vaccine - - BioPharm International


Sanofi Pasteur Makes Progress with Dengue Vaccine

BioPharm Bulletin

Sanofi Pasteur (Lyon, France) has announced positive results from Phase 2 trials of its dengue vaccine candidate based on technology licensed from Acambis plc (Cambridge, UK).

Dengue is one of the most common tropical diseases and a growing public health concern. Worldwide, 50–100 million people are affected and cases are appearing in northern Australia and Texas. The potential market for a dengue vaccine could be worth more than €1 billion annually. Sanofi Pasteur also plans to start a large-scale Phase 3 efficacy study in 2008, making this project the first tetravalent candidate dengue vaccine in the world to reach this stage of clinical development.

Acambis release
Sanofi Pasteur site

blog comments powered by Disqus



New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here